BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
313.55
-5.53 (-1.73%)
At close: 4:00PM EST

313.55 0.00 (0.00%)
After hours: 4:25PM EST

Stock chart is not supported by your current browser
Previous Close319.08
Open321.56
Bid300.00 x 100
Ask330.48 x 800
Day's Range312.98 - 322.78
52 Week Range249.17 - 388.67
Volume1,230,187
Avg. Volume1,208,375
Market Cap63.175B
Beta (3Y Monthly)1.97
PE Ratio (TTM)20.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
    MarketWatch6 hours ago

    Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

    Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.

  • Financial Times15 hours ago

    [$$] Possible delisting of BioLogics threatens Samsung’s growth strategy

    The long-term growth strategy of Samsung was thrown into doubt on Wednesday after regulators in South Korea suspended trading of a key biopharmaceutical affiliate that the conglomerate hoped would power ...

  • An expensive new medication is finally available for her rare disease — but she’s been fighting for two years to get it
    MarketWatchyesterday

    An expensive new medication is finally available for her rare disease — but she’s been fighting for two years to get it

    More and more rare-disease medications have been approved in recent years, but a tangle of complications can keep promising but expensive therapies out of reach for patients.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • 5 Pharma Stocks to Stay Away From
    InvestorPlace2 days ago

    5 Pharma Stocks to Stay Away From

    Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.

  • Ionis Pharmaceuticals Collects Royalties -- and Spends It All
    Motley Fool2 days ago

    Ionis Pharmaceuticals Collects Royalties -- and Spends It All

    With $2 billion in the bank, the biotech can afford to invest in the future.

  • 6 Pharmaceutical Stocks to Buy After the Midterms
    InvestorPlace5 days ago

    6 Pharmaceutical Stocks to Buy After the Midterms

    Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • GuruFocus.com6 days ago

    Jeff Auxier Comments on Biogen

    Guru stock highlight

  • GuruFocus.com6 days ago

    Jeff Auxier's Auxier Asset Management 3rd Quarter Commentary

    Namely, a strong dollar hurting export demand, tariffs, higher oil, transportation, labor and interest costs, which all can negatively impact profit margins. Rising mortgage rates, loss of deductions in high-tax states and overheated markets are hampering high-end housing. With US oil companies solidly profitable at $50 a barrel, fundamentals support lower fuel inputs as commodities will tend to trade close to the cost of production over time.

  • 7 Healthcare Stocks Soaring on Election Results
    InvestorPlace7 days ago

    7 Healthcare Stocks Soaring on Election Results

    The company will next report results on Feb. 1 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $10.99 billion. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues.

  • Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending September 30, 2018.

  • InvestorPlace9 days ago

    Biogen Stock Rebounds After Impressive Q3 Earnings

    Biogen Inc. (NASDAQ: BIIB) fell alongside the broad market selloff in October, but Biogen stock rallied rebounded when it reported third-quarter results. With BIIB stock price still in value territory at 15 times earnings and 11 times forward earnings, investors should take a closer look at the latest results.

  • AbbVie sees hit to Humira sales from European competition
    Reuters12 days ago

    AbbVie sees hit to Humira sales from European competition

    "We've seen discounting at ranges from as low as 10 percent to as high as around 80 percent," Chief Executive Officer Richard Gonzalez said on a conference call with analysts. The highest discounting was seen in Nordic countries, Gonzalez said, adding that the company believes discounting would likely "moderate" going forward. "We do not have evidence from prior European Union biosimilar launch dynamics that the pace of discounting will slow in the second year of availability," Leerink analyst Geoffrey Porges said.

  • Benzinga13 days ago

    Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said he likes Biogen Inc's (NASDAQ: BIIB ) management, but he doesn't like the hype around the new Alzheimer drug. People don't want to own ...

  • Biotech ETFs in Focus on String of Q3 Earnings Beat
    Zacks13 days ago

    Biotech ETFs in Focus on String of Q3 Earnings Beat

    Biotech ETFs draw attention post impressive Q3 results.

  • Sarissa Capital’s Alex Denner Bullish on Biogen (BIIB)
    Insider Monkey14 days ago

    Sarissa Capital’s Alex Denner Bullish on Biogen (BIIB)

    Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. Alexander John Denner, also known as Alex PhD. Before launching his own investment fund, Mr. Denner sharpened his investment skills as a portfolio manager at Viking Global, and as a Senior Managing Director at Icahn Capital […]

  • Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates
    Market Realist15 days ago

    Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates

    Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.

  • Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
    Market Realist15 days ago

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.

  • Recommendations for Shire as of October 30
    Market Realist15 days ago

    Recommendations for Shire as of October 30

    There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.

  • Shire’s Q3 2018 Earnings: Analyst Estimates
    Market Realist16 days ago

    Shire’s Q3 2018 Earnings: Analyst Estimates

    Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.

  • Investor's Business Daily16 days ago

    Biogen And Eisai May Be At Odds In Alzheimer's — So What Now?

    Biogen and Japanese partner Eisai may be at odds in developing a treatment for Alzheimer's disease, an analyst said Monday after a paradoxical presentation last week.

  • Insider Monkey17 days ago

    Clearbridge Investments Betting On A Shift From Growth and Momentum

    Clearbridge Investments published its third quarter commentary. The prevailing theme of the commentary is that we are on the cusp of a shift from growth and momentum outperformance to value investing. The winner of the current cycle, S&P 500 stocks, will perform poorly in the coming cycle and value stocks will outperform. Clearbridge mentions American […]

  • This experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsure
    MarketWatch17 days ago

    This experimental Alzheimer’s disease drug seemed promising — before the latest results left many unsure

    An experimental drug from drugmakers Biogen and Eisai emerged this summer with the potential to do what no other medication has been able to: slow the development of Alzheimer’s disease, a progressive and devastating disease marked by cognitive decline. With new study results, presented by the two companies early Thursday at a European conference, the uncertainty lingers on, even as it has become more complicated. Biogen shares (BIIB) dropped more than 3% in heavy Thursday trade before evening out to a 1.2% decline, while Eisai shares dropped 5.7% (JP:4523) Biogen shares also declined the day before the BAN2401 results, and dropped 1.8% in Friday premarket trade.

  • The October stock crash has wiped out $45.5B from Mass. health firms
    American City Business Journals19 days ago

    The October stock crash has wiped out $45.5B from Mass. health firms

    The health care and life sciences sector accounts for around 42 percent of all Massachusetts-based public companies.